{"filings":[{"id":2060557,"accession_number":"0001082554-26-000028","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2026-08-05T10:33:07+00:00","items":["2.02","9.01"],"status":"ready","headline":"United Therapeutics Reports Q2 2026 Revenue of $783.3M, Net Income Up 8% to $333M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues decreased 2% year-over-year to $783.3M; net income rose 8% to $333.0M.","Tyvaso DPI revenues grew 4% to $326.6M; Nebulized Tyvaso fell 18% to $126.0M.","Submitted NDAs for ralinepag tablets in PAH and Nebulized Tyvaso in IPF; potential approvals in 2027.","Repurchased ~2.76M shares under $1.5B ASR agreements; $500M remaining in buyback program.","R&D expense increased 9% to $146.3M driven by cardiopulmonary projects and contingent consideration."],"consensus_eps_estimate":null,"consensus_eps_actual":13.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":1564800000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1811723,"accession_number":"0001104659-26-086068","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2026-07-23T11:00:29+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"United Therapeutics appoints Victor Dzau to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded to 13 members; Victor Dzau, M.D., appointed effective July 22, 2026.","Dr. Dzau recently completed 12-year tenure as President of the National Academy of Medicine.","Initial grant: 380 RSUs and 1,190 stock options; pro-rata grant: 350 RSUs and 1,110 options.","No transactions exceeding $120,000 between Dr. Dzau and the company since last fiscal year.","Dr. Dzau will not serve on any Board committee initially."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1334156,"accession_number":"0001104659-26-078865","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2026-06-29T20:32:03+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"United Therapeutics shareholders approve 2026 Stock Incentive Plan with 1.5M new shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Plan adds 1,500,000 new shares; total reserve includes 2,413,730 carryover from prior plan plus returning shares.","Shareholders approved plan with 25,872,075 for, 10,070,290 against (72% support); advisory say-on-pay also passed.","All 12 director nominees elected; highest vote total was Kevin Tracey with 36,187,554 for, lowest was Christopher Causey with 32,342,983.","Plan allows options, SARs, restricted stock, RSUs, stock awards, and incentive bonuses; administered by Compensation Committee.","Effective June 26, 2026; no further grants under the 2015 plan; prior awards unaffected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91148,"accession_number":"0001082554-26-000021","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"UTHR Q1 revenue falls 2% to $781.5M; net income down 15%; $2B buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $781.5M (-2% YoY); net income $274.9M (-15%); diluted EPS $5.82 vs $6.63.","Tyvaso DPI grew 9% to $330.3M but Nebulized Tyvaso fell 22% to $127.2M; Orenitram up 12%.","Cost of sales surged 44% to $133.4M, with $26.8M inventory reserve loss on Tyvaso DPI supply agreement.","Board authorized $2B share repurchase; $1.5B accelerated buyback executed; $500M remaining.","Positive ADVANCE OUTCOMES and TETON-1 study results; plans to develop ralinepag DPI for PH/fibrosis."],"consensus_eps_estimate":null,"consensus_eps_actual":5.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":781500000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101085,"accession_number":"0001104659-26-036445","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"United Therapeutics' TETON-1 Tyvaso meets primary endpoint; FVC improvement 130.1 mL (p<0.0001)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TETON-1 met primary endpoint: change in absolute FVC by 130.1 mL vs placebo (p<0.0001) at week 52.","Nebulized Tyvaso significantly reduced risk of clinical worsening; benefits seen across all subgroups.","Integrated analyses of TETON-1 and TETON-2 show statistically significant treatment effects on primary and most secondary endpoints.","Plan to submit sNDA to FDA by summer 2026 for priority review to add IPF indication for Tyvaso.","Safety profile consistent with prior Tyvaso studies; no new safety signals observed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101084,"accession_number":"0001104659-26-025331","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"United Therapeutics authorizes $2B buyback, enters $1.5B accelerated share repurchase with Citi","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approves up to $2B stock repurchase program through March 9, 2027.","ASR agreements with Citibank total $1.5B: $750M uncollared and $750M collared.","Initial delivery of ~992,120 shares (uncollared, ~70%) and ~708,657 shares (collared, ~50%) on March 11, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101083,"accession_number":"0001104659-26-021869","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"United Therapeutics' ralinepag phase 3 meets primary endpoint; 55% risk reduction in PAH clinical worsening","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ralinepag reduced risk of clinical worsening by 55% vs placebo (HR 0.45, p<0.0001) in phase 3 ADVANCE OUTCOMES study.","Statistically significant improvements in 6MWD, NT-proBNP, and 47% increased odds of clinical improvement at Week 28.","80% of patients on dual background therapy; safety consistent with prostacyclin class; no new signals.","Company plans to submit NDA to FDA by second half of 2026.","Full results to be presented at upcoming international conference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101082,"accession_number":"0001082554-26-000007","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"United Therapeutics reports record $3.18B FY2025 revenue; EPS $27.86 diluted","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY 2025 revenue hit record $3.18B (+11% YoY); net income $1.33B ($27.86 diluted EPS) vs $1.20B ($24.64) in 2024.","Q4 revenue $790.2M (+7%); net income $364.3M ($7.70 diluted EPS) vs $301.3M ($6.19).","Tyvaso DPI sales $1.29B (+25% YoY); total Tyvaso $1.88B (+16%).","Orenitram sales $496.9M (+14% YoY).","Repurchased $1.0B of stock in 2025; litigation accrual reduced to $3M from $71.1M in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":27.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":3182700000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101081,"accession_number":"0001104659-26-005810","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2026-01-22T23:59:59+00:00","items":["5.02","5.03","7.01","9.01"],"status":"ready","headline":"United Therapeutics appoints Kevin J. Tracey to board; bylaws amended to lower shareholder vote threshold","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kevin J. Tracey, M.D., appointed to board effective Jan 21, 2026; awarded 1,220 RSUs under director compensation plan.","Bylaw amendments: create cure process for shareholder nomination deficiencies; lower shareholder vote to amend bylaws from 80% to majority.","Tracey is President/CEO of Feinstein Institutes, co-founder of SetPoint Medical; brings expertise in inflammation and bioelectronic medicine."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117430,"accession_number":"0001082554-25-000036","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"United Therapeutics reports record Q3 revenue $799.5M (+7% YoY); EPS $7.16 diluted, TETON-2 breakthrough","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $799.5M (+7% YoY); net income $338.7M (+10%); diluted EPS $7.16 vs $6.39.","Tyvaso DPI sales $336.2M (+22% YoY) driving total Tyvaso growth to $478M (+10%).","Orenitram $131.1M (+16%); Unituxin $47.9M (-22%) offset by price increases.","TETON-2 study in IPF shows breakthrough results; could significantly broaden therapeutic reach.","Entered $1B accelerated share repurchase in Aug 2025; received 2.6M shares in Q3 (combined $2B since Mar 2024)."],"consensus_eps_estimate":null,"consensus_eps_actual":20.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":2392500000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133839,"accession_number":"0001104659-25-085976","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"United Therapeutics' Tyvaso succeeds in TETON-2 IPF study, shows 95.6mL FVC improvement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TETON-2 met primary endpoint: Tyvaso improved absolute FVC by 95.6 mL vs placebo at week 52 (p<0.0001).","Statistically significant improvements in secondary endpoints including time to first clinical worsening, K-BILD, and DLCO.","Safety profile consistent with prior Tyvaso studies; no new safety signals observed.","Company plans FDA meeting to discuss expedited review; TETON-1 data expected H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133838,"accession_number":"0001104659-25-073163","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"United Therapeutics enters $1B accelerated share repurchase agreements with Citibank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Two ASR agreements with Citibank: $500M uncollared and $500M collared; total upfront payment $1B due Aug 4, 2025.","Uncollared ASR: initial delivery ~1.27M shares (75% of expected); final settlement expected Q4 2025 based on VWAP less discount.","Collared ASR: initial delivery ~850K shares (50% of expected); additional delivery after hedging; final settlement expected Q1 2026 with collar.","At July 30, 2025, company had ~45.2M shares outstanding; CEO cites confidence in intrinsic value and cash flow generation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133837,"accession_number":"0001628280-25-036543","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"United Therapeutics Reports Record Q2 2025 Revenue of $798.6M, Authorizes $1B Buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record total revenue of $798.6 million, up 12% year-over-year, driven by Tyvaso DPI growth of 22% to $315 million.","Board authorized up to $1 billion in share repurchases through March 31, 2026.","Phase 3 TETON 2 study of Nebulized Tyvaso in IPF complete; data expected September 2025.","Orenitram posted record quarterly revenue of $123.9 million, up 16% year-over-year.","Net income of $309.5 million, or $6.86 per basic share, up 11%."],"consensus_eps_estimate":null,"consensus_eps_actual":13.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":1593000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150584,"accession_number":"0001104659-25-063287","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Shareholders approve amended 2015 Stock Incentive Plan; increase share reserve by 950k shares and extend plan to 2035","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to 2015 Stock Incentive Plan, increasing share reserve by 950,000 shares to 14,770,000 total.","Plan expiration extended to April 24, 2035; Lead Independent Director retainer increased by $5,000 per year.","All 12 director nominees elected; say-on-pay passed with ~95% of votes cast.","The stock plan amendment passed with ~92% of votes cast; Ernst & Young ratified as auditor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150583,"accession_number":"0001082554-25-000024","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"United Therapeutics reports record Q1 revenue of $794.4M, up 17% YoY, EPS $6.63","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $794.4M (+17% YoY); net income $322.2M (+5%); diluted EPS $6.63 (+7% from $6.17).","Tyvaso family revenue $466.3M (+25% YoY), with Tyvaso DPI up 33% to $302.5M and nebulized Tyvaso up 13% to $163.8M.","R&D expense $149.0M (+43% YoY) driven by $30.0M milestone payments for drug delivery device technologies and adjustments to contingent consideration.","Upcoming catalysts: TETON 2 readout in IPF, UKidney first-in-human study; IND filings planned for UHeart and UThymoKidney."],"consensus_eps_estimate":null,"consensus_eps_actual":6.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":794400000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150582,"accession_number":"0001104659-25-039710","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"United Therapeutics enters $2.5B revolving credit facility, repays $200M of existing debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $2.5B unsecured revolving credit facility, with option to increase by up to $750M.","Borrowed $200M at closing to repay outstanding indebtedness under 2022 credit agreement.","Five-year maturity, with two potential one-year extensions at lenders' option.","Financial covenants: consolidated total leverage ≤3.50x and interest coverage ≥3.00x."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169543,"accession_number":"0001082554-25-000007","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"United Therapeutics reports record $2.88B revenue in FY2024, up 24% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $735.9M (+20% YoY); net income $301.3M vs $217.1M in Q4 2023.","Full-year net income $1.195B ($24.64 diluted EPS) vs $984.8M in 2023 (diluted EPS $19.81).","Tyvaso franchise revenue grew 31% to $1.62B in 2024, driven by Tyvaso DPI (up 41%).","Completed $1B accelerated share repurchase, repurchasing ~3.55M shares.","Recorded $71.1M litigation accrual for Sandoz; R&D expense up 18% on organ projects."],"consensus_eps_estimate":null,"consensus_eps_actual":24.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":2877400000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169542,"accession_number":"0001104659-25-002892","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"United Therapeutics presents at J.P. Morgan Healthcare Conference; no specific financials disclosed in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation slides filed as Exhibit 99.1 but full content not provided in the filing text.","Company provided business overview and update during Q&A session on January 13, 2025.","No material new financial or operational data available from this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186589,"accession_number":"0001082554-24-000049","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"United Therapeutics Q3 revenue $748.9M (+23% YoY); net income $309.1M (+16%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $748.9M, +23% YoY; net income $309.1M ($6.39 diluted EPS) vs $267.6M ($5.38).","Tyvaso product revenues $433.8M, +33% YoY driven by Tyvaso DPI uptake and PH-ILD expansion.","Accrued $65.1M litigation liability related to ongoing Sandoz patent case; final judgment pending.","Completed $1B accelerated share repurchase; repurchased ~3.55M shares during Q2-Q3 2024.","Management notes record revenue sixth straight quarter; Tyvaso remains key growth driver."],"consensus_eps_estimate":null,"consensus_eps_actual":18.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":2141500000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203162,"accession_number":"0001082554-24-000037","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"United Therapeutics Q2 2024 revenue up 20% to $714.9M, EPS $5.85","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $714.9M (+20% YoY); net income $278.1M ($5.85 diluted EPS) vs $259.2M ($5.24) in Q2 2023.","Tyvaso products revenue $398.2M (+25% YoY), led by Tyvaso DPI growth from PH-ILD launch.","Remodulin $147.3M (+16%), Orenitram $107.1M (+13%), Unituxin $51.7M (+17%).","R&D expense rose 57% to $139.6M, driven by upfront licensing payments and organ manufacturing.","Completed $300M tranche of $1B ASR; final $700M settlement expected in Q3 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":12.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":1392600000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219479,"accession_number":"0001104659-24-075375","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["5.02","5.07","7.01","9.01"],"status":"ready","headline":"United Therapeutics shareholders elect Jan Malcolm to board, approve stock plan amendment adding 1.32M shares","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jan Malcolm, former Minnesota Health Commissioner, elected to board; replaces Prof. Katherine Klein who did not stand for re-election.","Shareholders approved amendment to 2015 Stock Incentive Plan: adds 1,320,000 shares, extends expiration to April 25, 2034.","All 11 director nominees elected; advisory resolution on executive compensation passed with 94.8% of votes cast.","Ratification of Ernst & Young as independent auditor for 2024 approved by shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219478,"accession_number":"0001082554-24-000027","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"United Therapeutics Q1 2024 revenue up 34% to $677.7M; net income $306.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $677.7M (+34% YoY); Tyvaso product line grew 56% to $372.5M.","Net income $306.6M ($6.17 diluted EPS) vs $240.9M ($4.86 EPS) in Q1 2023.","Implemented $1B accelerated share repurchase with Citi; initial delivery of 3.275M shares.","Tyvaso DPI sales $227.5M (+92% YoY); nebulized Tyvaso $145.0M (+21%).","Revenue growth driven by increased patient utilization and Part D redesign tailwinds."],"consensus_eps_estimate":null,"consensus_eps_actual":6.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":677700000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239302,"accession_number":"0001104659-24-041160","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2024-03-29T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"United Therapeutics extends credit facility maturity to March 31, 2029","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Second one-year extension of $1.2B and $800M revolving credit facilities.","New maturity date March 31, 2029; effective March 29, 2024.","Facility capacity can be increased by up to $500M aggregate.","All other terms of the credit agreement remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239301,"accession_number":"0001104659-24-038478","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2024-03-25T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"United Therapeutics authorizes $1B accelerated share repurchase with Citibank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized up to $1B of common stock repurchase; ASR agreement signed with Citibank.","Initial delivery of ~3,275,199 shares (80% of estimated total) on March 27, 2024.","Final settlement to occur in Q2 ($300M) and Q3 2024 ($700M) based on VWAP.","Company also plans $400M credit facility paydown in 2024; $100M already paid in Q1.","CEO cites balance sheet strength and confidence in near-term prospects for buyback."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239300,"accession_number":"0001104659-24-027791","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"United Therapeutics moves to block Liquidia's PH-ILD product with preliminary injunction and FDA suit","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Filed preliminary injunction motion in Delaware on Feb 26, 2024, alleging Liquidia's PH-ILD product infringes U.S. Patent No. 11,826,327 (expires 2042).","Separately sued FDA in D.C., arguing Liquidia must submit a new NDA for PH-ILD, which would trigger a 30-month stay.","Liquidia's inhaled treprostinil is tentatively approved for PAH but not PH-ILD; United's Tyvaso is approved for both PAH and PH-ILD.","If injunction or stay granted, Liquidia cannot market its product for PH-ILD while patent litigation proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239299,"accession_number":"0001082554-24-000007","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2024-02-21T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"United Therapeutics reports record $2.33B 2023 revenue (+20% YoY); sues FDA over Liquidia NDA amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FY 2023 revenue $2.33B, net income $984.8M ($19.81 diluted EPS).","Tyvaso revenue grew 41% to $1.23B; Tyvaso DPI rose 362% to $731M.","Q4 2023 revenue $614.7M (+25% YoY), net income $217.1M (diluted EPS $4.36).","Filed lawsuit against FDA alleging agency improperly allowed Liquidia to amend pending NDA for PH-ILD, avoiding a 30-month stay of approval.","Litigation seeks to enforce Hatch-Waxman patent infringement stay pending resolution of separate patent case against Liquidia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256816,"accession_number":"0001104659-23-127766","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2023-12-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Federal Circuit cancels key Tyvaso patent; Liquidia may launch Yutrepia sooner","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Court affirmed IPR decision canceling claims of U.S. Patent No. 10,716,793 covering Tyvaso and Tyvaso DPI.","Liquidia can seek final FDA approval for Yutrepia unless the decision is reversed on further appeal.","United Therapeutics can request rehearing or petition the Supreme Court; patent claims remain valid until appeals exhausted.","Separate lawsuit filed Sep 2023 alleges Yutrepia amendments infringe new patent (11,826,327) expiring Jan 2042.","FDA tentatively approved Yutrepia for PAH in Nov 2021; final approval also requires lifting of District Court order."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256815,"accession_number":"0001104659-23-121738","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2023-11-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"United Therapeutics extends Adcirca license with Lilly through Dec 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive US marketing license for Adcirca extended from Dec 31, 2023 to Dec 31, 2026.","Other terms of the license agreement remain unchanged.","Adcirca (tadalafil) is for treatment of pulmonary hypertension in the US."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256814,"accession_number":"0001082554-23-000033","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2023-11-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"United Therapeutics Q3 revenue $609.4M (+18% YoY), net income $267.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $609.4M (+18% YoY); net income $267.6M ($5.38 diluted EPS) vs $239.3M ($4.91) Q3 2022.","Tyvaso DPI sales $205.1M (+225%) drove total Tyvaso $325.8M (+26%); nebulized Tyvaso declined 38% to $120.7M.","Remodulin $131.1M (+15%), Orenitram $92.0M (+5%), Unituxin $51.3M (+11%).","R&D expense $84.7M (+28%) from TETON fibrosis studies and organ manufacturing; SG&A $127.6M (+30%).","CEO cites record quarterly revenue; pipeline data expected in 2025; management reaffirms ~$4B annual run rate."],"consensus_eps_estimate":null,"consensus_eps_actual":15.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":1712800000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274171,"accession_number":"0001082554-23-000024","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"United Therapeutics Q2 2023: revenue $596.5M (+28%), net income $259.2M (+123%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $596.5M (+28% YoY), net income $259.2M (+123%), diluted EPS $5.24.","Tyvaso (including DPI) sales $318.9M, up 59% YoY, driven by patient growth and inventory build.","Orenitram sales $95.1M (+20%); Remodulin sales $127.2M (-4% YoY).","CEO expects $4B annual revenue run rate by mid-decade with continued expansion.","Share-based comp expense fell 79% to $13.8M due to stock price performance."],"consensus_eps_estimate":null,"consensus_eps_actual":10.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":1103400000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274170,"accession_number":"0001104659-23-083457","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2023-07-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"United Therapeutics wins Federal Circuit appeal in Liquidia patent litigation; Yutrepia approval delayed","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Federal Circuit affirmed Liquidia's Yutrepia infringes United Therapeutics' '793 patent; FDA approval blocked until patent expires May 14, 2027.","Court confirmed Liquidia would induce infringement by marketing Yutrepia; all '793 claims held valid over invalidity challenges.","Federal Circuit also affirmed certain claims of U.S. Patent No. 9,593,066 are either invalid or not infringed by Liquidia.","Both parties may request rehearing; PTAB IPR decision finding '793 unpatentable is on appeal by United Therapeutics.","District court order barring FDA final approval remains unless infringed claims are found invalid after exhaustion of appeals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274169,"accession_number":"0001104659-23-081249","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K/A","filed_at":"2023-07-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"United Therapeutics Board sets annual say-on-pay frequency until 2029","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board determined annual say-on-pay frequency, consistent with 2023 shareholder vote.","Next advisory vote on frequency expected at 2029 Annual Meeting.","Amendment filed solely to disclose frequency decision per Item 5.07(d)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291373,"accession_number":"0001104659-23-075515","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2023-06-28T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"United Therapeutics shareholders approve stock plan amendment increasing shares by 1M, extend plan to 2033","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to 2015 Stock Incentive Plan, increasing authorized shares by 1,000,000 and extending plan to April 20, 2033.","All 12 director nominees elected, with votes for ranging from 33.8M to 39.6M; broker non-votes of 1.4M on each.","Advisory vote on executive compensation approved: 38.7M for, 1.2M against, 220.6K abstain.","Frequency of future say-on-pay votes set at 1 year (39.1M votes).","Ratification of Ernst & Young as independent auditor approved: 40.7M for, 748.9K against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291372,"accession_number":"0001082554-23-000014","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2023-05-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"United Therapeutics Q1 revenue $506.9M (+10% YoY); Tyvaso sales up 39%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $240.9M flat YoY; diluted EPS $4.86 vs $5.03.","Tyvaso franchise net sales $238.4M (+39%) driven by Tyvaso DPI launch and label expansion.","Treprostinil products grew 16% combined; Orenitram hit record revenue of $88.2M.","R&D expense rose 20% to $82.9M, primarily on TETON IPF studies.","Effective tax rate decreased to 17% from 22% due to excess share-based compensation benefits."],"consensus_eps_estimate":null,"consensus_eps_actual":4.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":506900000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291371,"accession_number":"0001104659-23-047912","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2023-04-21T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"United Therapeutics amends bylaws to enhance stockholder proposal and nomination procedures","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amendments require additional background info on proposing stockholders and nominees, and representation on solicitation intentions.","Updates procedural mechanics for adjourned meetings, inspectors of election, and proxy revocability.","Eliminates stockholder list inspection at meetings; opts out of DGCL Section 116 for written delivery of notices.","Certificates and uncertificated shares must conspicuously state company is a public benefit corporation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312166,"accession_number":"0001104659-23-040233","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2023-03-31T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"United Therapeutics extends credit facility maturity to March 31, 2028","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Extended maturity of $1.2B and $800M unsecured revolving credit facilities by one year to March 31, 2028.","Extension effective March 31, 2023, per Section 2.7 of the Credit Agreement originally dated March 31, 2022.","Facilities may be increased by up to $500M aggregate subject to commitments and conditions.","No other changes to terms; borrowing capacity remains unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312165,"accession_number":"0001082554-23-000007","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2023-02-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"United Therapeutics reports record 2022 revenue of $1.94B, up 15% YoY; Q4 EPS $2.67","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year total revenues $1.94B, up 15% YoY; net income $727.3M ($15.00 diluted EPS).","Q4 revenues $491.5M, net income $132.1M ($2.67 diluted EPS).","Tyvaso net product sales $873M for 2022, up 44% YoY driven by Tyvaso DPI launch and PH-ILD expansion.","Treprostinil product sales grew 19% in 2022; company targets $4B revenue run rate by end of 2025.","Unituxin sales declined 10% to $182.9M; Adcirca down 26% due to generic competition."],"consensus_eps_estimate":null,"consensus_eps_actual":15.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":1936300000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312164,"accession_number":"0001104659-23-001967","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"United Therapeutics presents at J.P. Morgan Healthcare Conference; no material updates in filing exhibit","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company presented business overview at 41st annual J.P. Morgan Healthcare Conference on Jan 9, 2023.","Presentation slides furnished as Exhibit 99.1 contain only a title slide; no financial or pipeline details provided.","Webcast available live and archived for 30 days via company website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330733,"accession_number":"0001082554-22-000028","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2022-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"United Therapeutics Q3 revenue $516M (+16% YoY); net income $239M (+47%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income per diluted share $4.91; Tyvaso revenues $257.7M (+57% YoY) driven by Tyvaso DPI launch.","Tyvaso achieved $1B annual run-rate; management targets 6,000 patients on Tyvaso by year-end.","R&D expense $66.1M (-17% YoY) due to fair value adjustments; PERFECT study discontinued per DSMC.","TETON 2 study of Tyvaso in IPF enrolled first patient October 2022; TETON 1 enrollment ongoing.","Remunity Pump launched patient-filled version in September 2022 for monthly cassette shipments."],"consensus_eps_estimate":null,"consensus_eps_actual":12.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":1444800000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330732,"accession_number":"0001104659-22-107409","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2022-10-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"United Therapeutics enrolls first patient in Phase 3 TETON 2 study of Tyvaso for IPF","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient enrolled in Phase 3 TETON 2 study of Tyvaso (treprostinil) Inhalation Solution for idiopathic pulmonary fibrosis (IPF).","Study targets 396 adult IPF patients at sites outside the US and Canada; 52-week treatment evaluating forced vital capacity (FVC).","Tyvaso is already FDA-approved for PH-ILD but not for IPF without documented pulmonary hypertension.","TETON program builds on positive FVC impact observed in the INCREASE study of inhaled treprostinil in IPF patients with PH."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348245,"accession_number":"0001104659-22-101298","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2022-09-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"United Therapeutics terminates PERFECT study of Tyvaso for PH associated with COPD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DSMC recommended termination after routine safety and efficacy analysis.","Study evaluated Tyvaso (treprostinil) Inhalation Solution for pulmonary hypertension with COPD.","Company will review available data and share results with the scientific community.","Tyvaso is already approved for PAH and PH-ILD; termination affects a potential label expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348244,"accession_number":"0001104659-22-096701","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2022-09-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Court rules Liquidia's Yutrepia infringes United Therapeutics patent; injunction expected through 2027","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["District Court finds Liquidia would induce infringement of '793 patent claims; claims not invalid.","Court expects to enter injunction barring FDA approval of Yutrepia until '793 patent expires May 14, 2027.","Court found Yutrepia would infringe '066 patent claims but held those claims invalid; United Therapeutics evaluating appeal.","PTAB recently invalidated '793 patent in IPR; United Therapeutics seeks rehearing and plans appeal; patent remains valid during appeals.","Both parties have right to appeal; United Therapeutics will vigorously defend IP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348243,"accession_number":"0001082554-22-000021","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2022-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"United Therapeutics Q2 2022 revenue up 5% to $466.9M; net income down 33%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $466.9M (+5% YoY); net income $116.0M ($2.41 diluted EPS) vs $172.6M ($3.65) in Q2 2021.","Tyvaso sales $201.0M (+31%) from PH-ILD label expansion; ~500 additional Tyvaso patients in Q2.","Share-based compensation $65.5M (+125%), driven by STAP expense from 31% stock price increase.","FDA approved Tyvaso DPI in May 2022 for PAH and PH-ILD; commercial shipments began in June.","CMS updated Tyvaso coverage for PH-ILD effective June 5, 2022, supporting further patient growth."],"consensus_eps_estimate":null,"consensus_eps_actual":7.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":928800000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":364938,"accession_number":"0001104659-22-075294","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2022-06-28T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Shareholders approve 500,000-share increase and extension of 2015 Stock Incentive Plan to 2032","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Plan share reserve increased by 500,000 to 11.5M shares; expiration extended to April 25, 2032.","All 9 director nominees elected with majority vote; advisory say-on-pay passed with 38.9M for, 0.7M against.","Plan amendment received 34.8M votes for (85.8% of votes cast); Ernst & Young ratified as auditor for 2022.","Amendment effective June 27, 2022; prior plan was approved by shareholders in June 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":364937,"accession_number":"0001104659-22-064024","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2022-05-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA approves United Therapeutics' Tyvaso DPI for PAH and PH-ILD; launch underway","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved Tyvaso DPI (treprostinil inhalation powder) for PAH (WHO Group 1) and PH-ILD (WHO Group 3).","First dry powder inhaler approved for PAH and PH-ILD; patient availability expected June 2022.","BREEZE study (51 PAH patients) demonstrated safety/tolerance and improved 6-minute walk distance.","TYVASO DPI and Tyvaso Inhalation Solution are only FDA-approved therapies for PH-ILD.","Commercial launch activities underway, offering convenient treprostinil delivery via hand-held inhaler."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":364936,"accession_number":"0001082554-22-000014","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2022-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"United Therapeutics Q1 revenue up 22% to $461.9M; diluted EPS $5.03 vs $0.61 YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $461.9M (+22% YoY) driven by Tyvaso ($172M, +40%) and Unituxin ($55.6M, +27%) on label expansion and Japan launch.","Net income $239.9M (diluted EPS $5.03) vs $28.3M ($0.61) in Q1 2021; earnings surge primarily due to strong revenue and lower R&D spend.","Tyvaso DPI NDA under FDA review with decision expected in May 2022; company awaits outcome of citizen petition and inspection issues.","Phase 3 TETON 1 & 2 studies for IPF, PERFECT for PH-COPD, and ADVANCE trials for ralinepag are enrolling or commencing.","Orenitram revenue grew 14% YoY to $82.8M on volume and price; Remodulin flat at $131.7M with U.S. decline offset by international orders."],"consensus_eps_estimate":null,"consensus_eps_actual":5.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":461900000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":364935,"accession_number":"0001104659-22-048558","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2022-04-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CMS expands Tyvaso coverage to include PH-ILD; effective June 5, 2022","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CMS updated Local Coverage Determination for Tyvaso (treprostinil) to include pulmonary hypertension associated with interstitial lung disease.","Coverage effective June 5, 2022, after a 45-day notice period as announced April 21, 2022.","Tyvaso is a treprostinil inhalation solution marketed by United Therapeutics for pulmonary hypertension."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":364934,"accession_number":"0001104659-22-041375","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2022-04-01T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"United Therapeutics enters $2B credit agreement, draws $800M to refinance existing debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $2B unsecured revolving credit facility with $1.2B Tranche A and $800M Tranche B; can be increased by up to $500M.","Borrowed $800M at closing to repay outstanding indebtedness under 2018 credit agreement; no penalties for early termination.","Maturity five years from March 31, 2022, with two possible one-year extensions at borrower's request.","Interest at Adjusted Term SOFR or base rate plus margin tied to leverage ratio; covenant limits total debt/EBITDA to 3.00x (3.50x after acquisitions).","Financial covenants also require interest coverage ratio >= 3.00x; customary events of default and change of control clause."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":384539,"accession_number":"0001082554-22-000006","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2022-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"United Therapeutics FY2021 revenue $1.69B (+14% YoY); Tyvaso DPI decision pushed to May 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2021 revenue $1.69B, up 14% YoY; Q4 revenue $415M, up 8% YoY.","Net income $475.8M ($10.60 basic GAAP EPS); non-GAAP diluted EPS $15.26.","Tyvaso net sales $607.5M in 2021, up 26% YoY; Remodulin down 1% to $513.7M.","Tyvaso DPI NDA extended to May 2022 after FDA requested info on pulmonary safety related to Citizen Petition.","Patient count reached all-time high; target of 6,000 Tyvaso patients by end of 2022 reaffirmed."],"consensus_eps_estimate":null,"consensus_eps_actual":10.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":1685500000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":384538,"accession_number":"0001104659-22-004549","cik":1082554,"company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","form_type":"8-K","filed_at":"2022-01-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA accepts United Therapeutics' resubmitted NDA for Tyvaso DPI as Class 1 review; target date Feb 2022","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted resubmission of NDA for Tyvaso DPI as a Class 1 response after Complete Response Letter in Oct 2021.","User fee goal date (PDUFA) set for February 2022, indicating expedited review.","Tyvaso DPI is an inhaled treprostinil product for pulmonary arterial hypertension.","Resubmission made on Dec 27, 2021, and accepted for review on Jan 18, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":24058810000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-01-18T23:59:59+00:00|384538"}